ArticleGene therapy2000
Gene transfer of virally encoded chemokine antagonists vMIP-II and MC148 prolongs cardiac allograft survival and inhibits donor-specific immunity.
Article in Gene therapy, 2000. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 74 citations in OpenAlex.
- Review
- Deriving Immune Modulating Drugs from Viruses-A New Class of Biologics.Journal of clinical medicine · 2020Review
- Kaposi sarcoma.Nature reviews. Disease primers · 2019Review
- Chemokine Subversion by Human Herpesviruses.Journal of innate immunity · 2018Review
- Chemokines encoded by herpesviruses.Journal of leukocyte biology · 2017Review
- Mechanisms of immunomodulation by mammalian and viral decoy receptors: insights from structures.Nature reviews. Immunology · 2017Review
- International Union of Basic and Clinical Pharmacology. [corrected]. LXXXIX. Update on the extended family of chemokine receptors and introducing a new nomenclature for atypical chemokine receptors.Pharmacological reviews · 2014Review
- Characterization of the interactions of vMIP-II, and a dimeric variant of vMIP-II, with glycosaminoglycans.Biochemistry · 2010Article
- Viral macrophage inflammatory protein-II improves acute rejection in allogeneic rat kidney transplants.World journal of urology · 2010Article
- Platelet-derived chemokines: pathophysiology and therapeutic aspects.Cellular and molecular life sciences : CMLS · 2010Review
- Gene transfer of RANTES and MCP-1 chemokine antagonists prolongs cardiac allograft survival.Gene therapy · 2006Article
- Fugetaxis: active movement of leukocytes away from a chemokinetic agent.Journal of molecular medicine (Berlin, Germany) · 2005Review
- Migration of antigen-specific T cells away from CXCR4-binding human immunodeficiency virus type 1 gp120.Journal of virology · 2004Article
- Poxvirus immunomodulatory strategies: current perspectives.Journal of virology · 2003Review
- Kaposi's sarcoma-associated herpesvirus immunoevasion and tumorigenesis: two sides of the same coin?Annual review of microbiology · 2003Review
- Viral mimicry of cytokines, chemokines and their receptors.Nature reviews. Immunology · 2003Review
- Molecular virology of Kaposi's sarcoma-associated herpesvirus.Philosophical transactions of the Royal Society of London. Series B, Biological sciences · 2001Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
Abstract
Introducing immunomodulatory molecules into allografts by gene transfer may avoid the side-effects of systemic immunosuppression. vMIP-II and MC148 are two recently identified chemokine homologues encoded by human herpes virus 8 and Molluscum contagiosum, respectively, that have antagonistic activities against multiple different CC and CXC chemokine receptors. We hypothesized that introduction of these molecules into cardiac allografts may block leukocyte infiltration into the grafts and prolong survival. Vascularized and nonvascularized cardiac allografts in mice were performed and plasmid DNA encoding vMIP-II, MC148 and/or vIL-10 was transferred into the allograft at the time of transplantation. Gene transfer of either vMIP-II or MC148 into cardiac allografts markedly prolonged graft survival. Combining gene transfer of either one of these chemokine antagonists with vIL-10 gene transfer, which has a mechanistically different immunosuppressive action, further enhanced graft survival. vMIP-II and MC148 gene transfer both resulted in a marked decrease of donor-specific cytotoxic T lymphocytes (CTL) infiltrating the grafts and inhibited alloantibody production. These results demonstrate that plasmid-mediated gene transfer of virally encoded chemokine antagonists vMIP-II and MC148 can block donor-specific lymphocyte immunity within cardiac allografts and prolong graft survival. This is a new mechanistic approach to analyze, treat, and prevent graft rejection. Delivery of these or related molecules by gene transfer or conventional pharmacologic means may represent a novel therapeutic modality for alloactivation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.